Q1 EPS Forecast for Unicycive Therapeutics Lifted by Analyst

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) – Equities research analysts at HC Wainwright upped their Q1 2026 earnings per share (EPS) estimates for Unicycive Therapeutics in a research note issued on Tuesday, March 31st. HC Wainwright analyst S. Ramakanth now expects that the company will earn ($0.05) per share for the quarter, up from their previous estimate of ($0.35). The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($0.23) per share. HC Wainwright also issued estimates for Unicycive Therapeutics’ Q2 2026 earnings at ($0.52) EPS, Q3 2026 earnings at ($0.33) EPS, Q4 2026 earnings at ($0.76) EPS, FY2026 earnings at ($1.67) EPS, FY2027 earnings at ($0.90) EPS, FY2028 earnings at $1.60 EPS, FY2029 earnings at $5.70 EPS and FY2030 earnings at $7.45 EPS.

Unicycive Therapeutics (NASDAQ:UNCY) last posted its quarterly earnings data on Monday, March 30th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.36).

Several other research firms also recently weighed in on UNCY. Guggenheim dropped their price target on Unicycive Therapeutics from $46.00 to $40.00 and set a “buy” rating on the stock in a research note on Thursday. Westpark Capital initiated coverage on Unicycive Therapeutics in a research note on Thursday, February 19th. They issued a “buy” rating for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Unicycive Therapeutics in a report on Friday, March 27th. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $27.67.

Unicycive Therapeutics Price Performance

UNCY stock opened at $6.93 on Friday. The firm has a market cap of $174.91 million, a price-to-earnings ratio of -3.19 and a beta of 1.81. The business’s fifty day simple moving average is $6.67 and its two-hundred day simple moving average is $5.82. Unicycive Therapeutics has a twelve month low of $3.71 and a twelve month high of $11.00.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in UNCY. Millennium Management LLC acquired a new stake in Unicycive Therapeutics during the 4th quarter worth about $5,856,000. JPMorgan Chase & Co. raised its stake in shares of Unicycive Therapeutics by 11,698.4% during the 2nd quarter. JPMorgan Chase & Co. now owns 21,709 shares of the company’s stock valued at $104,000 after buying an additional 21,525 shares during the last quarter. Citadel Advisors LLC acquired a new position in shares of Unicycive Therapeutics in the 3rd quarter valued at about $182,000. OMERS ADMINISTRATION Corp acquired a new position in shares of Unicycive Therapeutics in the 4th quarter valued at about $451,000. Finally, Squarepoint Ops LLC purchased a new stake in shares of Unicycive Therapeutics in the third quarter worth about $512,000. 40.42% of the stock is currently owned by institutional investors and hedge funds.

Key Unicycive Therapeutics News

Here are the key news stories impacting Unicycive Therapeutics this week:

• Positive Sentiment: Piper Sandler reaffirmed a Buy on Unicycive, maintaining analyst support that can sustain demand among growth/biotech investors. Piper Sandler Remains a Buy on Unicycive Therapeutics (UNCY)
• Positive Sentiment: Guggenheim kept a Buy rating and a high $40 price target (down from $46), signaling continued bullish conviction and large upside vs. the current share price — a support for longer‑term investors. Benzinga
• Positive Sentiment: Coverage from Noble Financial includes a reportedly positive Q3 outlook and modest intraquarter upward tweaks, which may limit downside for near‑term earnings expectations. Noble Financial Has Positive Forecast for UNCY Q3 Earnings
• Neutral Sentiment: Noble Financial made small upward revisions to certain near‑term quarters (Q1 and a slight Q2 tweak), but also trimmed its FY2026 outlook — a mixed signal that tempers how much the stock should move on those changes alone.
• Negative Sentiment: HC Wainwright issued broad downgrades across Q2–Q4 2026 and materially cut FY2026–FY2030 EPS forecasts (FY2026 from ~($0.94) to ($1.67); FY2028–FY2030 reductions are especially large). Those cuts imply slower near‑term profitability and push out the path to the previously modeled upside, which is likely the main driver of downward pressure on the share price.
• Negative Sentiment: Noble also lowered its Q4 2026 and FY2026 numbers in the same reporting window, which adds further downward bias to consensus near‑term earnings expectations.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.